TABLE 2.

Interference between RF, ANA, and AECA titers^a

Patient no.	Patient disease	Titer			ENA specificityc
		AECA (index)	RF (IU/ml)	ANAb
1	Phlebitis	72	120	<80
2	Prostate resection	68	125	<80
3	Fibromyalgia	155	15	<80
4	Renal transplantation	51	80	<80
5	Churg-Strauss syndrome	90	1,200	<80
6	Churg-Strauss syndrome	37	150	<80
7	Lung embolism	92	70	<80
8	Sjögren's syndrome	646	290	<80
9	Sjögren's syndrome	25	200	<80
10	Rheumatoid arthritis	22	270	<80
11	Rheumatoid arthritis	82	125	<80
12	Rheumatoid arthritis	52	1,750	<80
13	Rheumatoid arthritis	66	410	<80
14	Rheumatoid arthritis	34	90	<80
15		118	260	<80
16	Rheumatoid arthritis	55	100	<80
17	Rheumatoid arthritis	17	115	<80
18	Rheumatoid arthritis	33	240	<80
19	Rheumatoid arthritis	25	330	<80
20	Rheumatoid arthritis	91	165	<80
21	Rheumatoid arthritis	202	1,500	<80
22	Rheumatoid arthritis	231	380	<80
23	Rheumatoid arthritis	118	110	<80
24	Rheumatoid arthritis	176	195	<80
25	Rheumatoid arthritis	78	1000	320 (h)	0
26	Rheumatoid arthritis	33	5,600	160 (h, nue)	0
27	Sjögren's syndrome	39	140	320 (speck)	SS-A
28	Sjögren's syndrome	23	170	>1,280 (speck)	SS-A
29	Sjögren's syndrome	59	500	>1,280 (speck)	SS-A/SS-B
30	Sjögren's syndrome	90	740	>1,280 (speck)	SS-A
31	Systemic sclerosis	80	385	>1,280 (centro)	CENP-B
32	Systemic sclerosis	79	350	>1,280 (h, nuc)	PM-Scl
33	Systemic sclerosis	41	765	>1,280 (h)	U1-RNP
34	Systemic sclerosis	77	300	>1,280 (centro)	CENP-B
35	Systemic sclerosis	144	100	>1,280 (centro)	CENP-B
36	Systemic sclerosis	26	40	>1,280 (centro)	CENP-B
37	Severe Raynaud's phenomenon	113	765	>1,280 (h)	U1-RNP
38	Sclerosis polymyositis overlap syndrome	32	90	>1,280 (nuc)	PM-Scl
39	Lupus	34	250	>1,280 (speck)	SS-A
40	Lupus	189	95	>1,280 (speck)	PCNA
41	Lupus	257	40	160 (h)	0
42	Lupus	158	35	640 (speck)	SS-A
43	Lupus	165	25	>1,280 (h)	dsDNA (200 IU/ml)
44	Mixed connective tissue disease	56	560	640 (speck)	0
45	Mixed connective tissue disease	113	45	>1,280 (speck)	RNP
46	Mixed connective tissue disease	252	40	>1,280 (speck)	SS-A/RNP
47	Primary antiphospholipid syndrome	199	95	>1,280 (h)	dsDNA (850 IU/ml)
48	Primary antiphospholipid syndrome	153	30	160 (centro)	CENP-B
49	Primary antiphospholipid syndrome	305	25	160 (h)	0
50	Hashimoto's thyroiditis	27	160	160 (h)	0

^aThe AECA (PNS-ELISA) anti-human IgG RF, and ANA titers in 50 serum samples were assessed by the assays described in Materials and Methods. Comparisons of the data obtained by the assays for AECA and ANA and the assays for AECA and RF were performed according to Spearman's rank test; r values were 0.13 (P = 0.38) and −0.20 (P = 0.17), respectively. The reference values for AECA, RF, and ANA are <100, <30 IU/ml, and <80, respectively.

^bHEp-2 patterns of ANA fluorescence are indicated as follows: centro, centromere; h, homogeneous; nuc, nucleolar; speck, speckled.

^c0, none.